JP2021525731A5 - - Google Patents
Info
- Publication number
- JP2021525731A5 JP2021525731A5 JP2020566664A JP2020566664A JP2021525731A5 JP 2021525731 A5 JP2021525731 A5 JP 2021525731A5 JP 2020566664 A JP2020566664 A JP 2020566664A JP 2020566664 A JP2020566664 A JP 2020566664A JP 2021525731 A5 JP2021525731 A5 JP 2021525731A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- amino acid
- acid sequence
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023201568A JP7726967B2 (ja) | 2018-05-28 | 2023-11-29 | 多重特異性結合タンパク質及びその改善 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677137P | 2018-05-28 | 2018-05-28 | |
| US62/677,137 | 2018-05-28 | ||
| PCT/US2019/034186 WO2019231920A1 (en) | 2018-05-28 | 2019-05-28 | Multi-specific binding proteins and improvements thereon |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023201568A Division JP7726967B2 (ja) | 2018-05-28 | 2023-11-29 | 多重特異性結合タンパク質及びその改善 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021525731A JP2021525731A (ja) | 2021-09-27 |
| JP2021525731A5 true JP2021525731A5 (enExample) | 2022-06-07 |
Family
ID=68697331
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566664A Pending JP2021525731A (ja) | 2018-05-28 | 2019-05-28 | 多重特異性結合タンパク質及びその改善 |
| JP2023201568A Active JP7726967B2 (ja) | 2018-05-28 | 2023-11-29 | 多重特異性結合タンパク質及びその改善 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023201568A Active JP7726967B2 (ja) | 2018-05-28 | 2023-11-29 | 多重特異性結合タンパク質及びその改善 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210214436A1 (enExample) |
| EP (2) | EP3802581A4 (enExample) |
| JP (2) | JP2021525731A (enExample) |
| KR (1) | KR20210013160A (enExample) |
| CN (2) | CN112533944A (enExample) |
| AU (1) | AU2019277138B2 (enExample) |
| BR (1) | BR112020024235A2 (enExample) |
| CA (1) | CA3101604A1 (enExample) |
| CL (1) | CL2020003071A1 (enExample) |
| EA (2) | EA202091977A1 (enExample) |
| IL (1) | IL278943A (enExample) |
| MX (1) | MX2020012905A (enExample) |
| PE (1) | PE20210167A1 (enExample) |
| SG (1) | SG11202011763YA (enExample) |
| WO (1) | WO2019231920A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978171A1 (en) * | 2015-03-10 | 2016-09-15 | J.H. Frederik Falkenburg | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| KR20240007775A (ko) | 2016-12-08 | 2024-01-16 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| JP2021534096A (ja) * | 2018-08-08 | 2021-12-09 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| AU2020209991B2 (en) * | 2019-01-17 | 2024-11-14 | Immunocore Limited | Formulations |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN116096758A (zh) * | 2020-05-01 | 2023-05-09 | 诺华股份有限公司 | 工程化免疫球蛋白 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CN113754771A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pdl1×egfr的双特异性抗体 |
| CN116368154A (zh) * | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
| US20250223379A1 (en) * | 2021-01-11 | 2025-07-10 | Adimab, Llc | Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| JP2024512135A (ja) * | 2021-03-31 | 2024-03-18 | ヤンセン バイオテツク，インコーポレーテツド | 免疫エフェクター細胞再指向のための材料及び方法 |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| US12441816B2 (en) | 2021-09-21 | 2025-10-14 | Qilu Puget Sound Biotherapeutics Corporation | Heterodimeric Fc for making fusion proteins and bispecific antibodies |
| WO2023131053A1 (zh) * | 2022-01-05 | 2023-07-13 | 苏州系统医学研究所 | 一种t细胞受体及其制备方法和用途 |
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| AU2024287954A1 (en) * | 2023-07-07 | 2026-01-22 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Egfr/c-met bispecific binding protein and use thereof |
| WO2025050020A1 (en) * | 2023-08-30 | 2025-03-06 | Mink Therapeutics, Inc. | Novel t cell receptors that bind to preferentially expressed antigen in melanoma (prame) and methods of use thereof |
| WO2025233431A1 (en) * | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| WO2025247255A1 (zh) * | 2024-05-28 | 2025-12-04 | 映恩生物科技(上海)有限公司 | 一种抗dll3抗体、抗体药物偶联物及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10156482A1 (de) * | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
| JP2008514685A (ja) * | 2004-10-01 | 2008-05-08 | メディジーン リミテッド | 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するｔ細胞レセプター |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| AU2008337517B2 (en) | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| WO2010017103A2 (en) | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| HUE033245T2 (hu) * | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| US9562110B2 (en) * | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| JP6385357B2 (ja) * | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 |
| JP6594855B2 (ja) * | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| EP3227332B1 (en) * | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| WO2016100533A2 (en) * | 2014-12-17 | 2016-06-23 | Intrexon Corporation | Intercalated single-chain variable fragments |
| CA2973720A1 (en) | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2016134371A2 (en) | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| EP3095792A1 (en) * | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| AU2018219887B2 (en) * | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110461361A (zh) * | 2017-02-10 | 2019-11-15 | 蜻蜓治疗公司 | 结合bcma、nkg2d和cd16的蛋白 |
| SG11201907638QA (en) * | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding cd33, nkg2d and cd16 |
| CN110944661A (zh) * | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| EP3668893A4 (en) * | 2017-08-16 | 2021-08-04 | Dragonfly Therapeutics, Inc. | PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1 |
| SG11202001930QA (en) * | 2017-09-07 | 2020-04-29 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| BR112020016944A2 (pt) * | 2018-02-20 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos |
| WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
-
2019
- 2019-02-20 EA EA202091977A patent/EA202091977A1/ru unknown
- 2019-05-28 PE PE2020001934A patent/PE20210167A1/es unknown
- 2019-05-28 CN CN201980049197.9A patent/CN112533944A/zh active Pending
- 2019-05-28 EA EA202092907A patent/EA202092907A1/ru unknown
- 2019-05-28 SG SG11202011763YA patent/SG11202011763YA/en unknown
- 2019-05-28 CN CN202311768455.3A patent/CN117964773A/zh active Pending
- 2019-05-28 AU AU2019277138A patent/AU2019277138B2/en active Active
- 2019-05-28 BR BR112020024235-7A patent/BR112020024235A2/pt unknown
- 2019-05-28 KR KR1020207036884A patent/KR20210013160A/ko not_active Ceased
- 2019-05-28 CA CA3101604A patent/CA3101604A1/en active Pending
- 2019-05-28 EP EP19812582.5A patent/EP3802581A4/en not_active Ceased
- 2019-05-28 MX MX2020012905A patent/MX2020012905A/es unknown
- 2019-05-28 JP JP2020566664A patent/JP2021525731A/ja active Pending
- 2019-05-28 US US17/058,335 patent/US20210214436A1/en active Pending
- 2019-05-28 WO PCT/US2019/034186 patent/WO2019231920A1/en not_active Ceased
- 2019-05-28 EP EP24215746.9A patent/EP4537904A3/en active Pending
-
2020
- 2020-11-24 IL IL278943A patent/IL278943A/en unknown
- 2020-11-26 CL CL2020003071A patent/CL2020003071A1/es unknown
-
2023
- 2023-11-29 JP JP2023201568A patent/JP7726967B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525731A5 (enExample) | ||
| Hosseini et al. | Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials | |
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| Thakur et al. | Cancer therapy with bispecific antibodies: Clinical experience | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| Zhang et al. | The development of bispecific antibodies and their applications in tumor immune escape | |
| May et al. | Advances in bispecific biotherapeutics for the treatment of cancer | |
| Weidle et al. | Tumor-antigen–binding bispecific antibodies for cancer treatment | |
| JP2021512630A5 (enExample) | ||
| Moon et al. | Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody | |
| JP2017531687A5 (enExample) | ||
| IL319102A (en) | Guidance and navigation control proteins and method for producing and using them | |
| US20230028399A1 (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| JP2020522473A5 (enExample) | ||
| JP2020531525A5 (enExample) | ||
| RU2020111554A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| Satta et al. | Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors | |
| JP2024519335A (ja) | がん免疫療法のための投薬レジメン | |
| Dhimolea et al. | World bispecific antibody summit, September 27–28, 2011, Boston, MA | |
| Kim et al. | Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors | |
| CN118786142A (zh) | 用于治疗肿瘤的ror1 car或ror1/cd19双car t细胞 | |
| JP2023512456A5 (enExample) | ||
| Brandão et al. | Bispecific Antibodies: An Emerging Concept in Antibody-Based Cancer Therapies |